[FCSC] Fibrocell Science Inc

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.69 Change: -0.06 (-8%)
Ext. hours: Change: 0 (0%)

chart FCSC

Refresh chart

Strongest Trends Summary For FCSC

FCSC is in the long-term down -49% in 1 year and down -96% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Fibrocell Science, Inc., an autologous cell therapy company, focuses on developing various treatments for skin diseases and conditions with unmet medical needs. The company, through its proprietary autologous fibroblast technology, Fibrocell, develops biologic solutions and medical applications of azficel-T for restrictive burn scarring and vocal cord scarring conditions; and biologic products for patients with rare genetic skin and tissue disorders. It has collaboration agreements with Intrexon Corporation for using genetically-modified fibroblasts for treating rare and serious skin, and connective tissue diseases; and University of California, Los Angeles to focus on skin-derived stem cells and other ways to convert skin cells to other cell types. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was founded in 1995 and is headquartered in Exton, Pennsylvania.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 234.48% Sales Growth - Q/Q246.43% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-48.97% ROE-90.53% ROI
Current Ratio5.79 Quick Ratio5.7 Long Term Debt/Equity Debt Ratio0.27
Gross Margin-407.93% Operating Margin-7871.34% Net Profit Margin-6148.17% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities150 K Cash From Investing Activities-110 K Cash From Operating Activities-4.24 M Gross Profit50 K
Net Profit-8.53 M Operating Profit-6.86 M Total Assets41.18 M Total Current Assets34.93 M
Total Current Liabilities6.03 M Total Debt Total Liabilities18.9 M Total Revenue190 K
Technical Data
High 52 week4.8 Low 52 week1.5 Last close2.01 Last change4.15%
RSI56.35 Average true range0.15 Beta0.53 Volume94.25 K
Simple moving average 20 days2.85% Simple moving average 50 days7.42% Simple moving average 200 days-8.41%
Performance Data
Performance Week-0.99% Performance Month4.15% Performance Quart-2.43% Performance Half1.01%
Performance Year-33.55% Performance Year-to-date34% Volatility daily3.31% Volatility weekly7.4%
Volatility monthly15.17% Volatility yearly52.56% Relative Volume107.4% Average Volume110.19 K
New High New Low

News

2019-04-17 09:14:00 | These 2 Biotech Stocks Are No Longer 'Off the Radar'

2019-04-17 07:48:11 | Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal

2019-04-16 19:26:11 | ProQR Initiates Dosing in Phase II/III Eye Disorder Study

2019-04-16 10:59:02 | Fibrocell Out-licenses Skin Disease Gene Therapy, Stock Rises

2019-04-15 13:22:55 | Fibrocell signs $135M deal to advance therapy for 'butterfly children'

2019-04-15 06:30:00 | Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy

2019-04-03 08:00:00 | Fibrocell Announces Board Member Christine St.Clare Honored by National Association of Corporate Directors

2019-03-27 07:30:00 | Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007

2019-03-20 08:00:00 | Fibrocell to Host Conference Call & Webcast for Full Year 2018 Financial Results and Recent Highlights on March 27, 2019

2019-02-06 08:00:00 | Fibrocell to Present at 21st Annual BIO CEO & Investor Conference

2019-01-16 08:00:00 | Fibrocell to Present at Phacilitate Leaders World 2019

2018-12-11 08:00:00 | Fibrocell Receives $900,000 Investment from EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation

2018-12-04 14:16:31 | What Kind Of Shareholders Own Fibrocell Science Inc NASDAQ:FCSC?

2018-11-19 08:30:00 | Market Trends Toward New Normal in Fibrocell Science, Sears Hometown and Outlet Stores, Apellis Pharmaceuticals, Sigma Labs, Highpower International, and Nicholas Financial — Emerging Consolidated Expectations, Analyst Ratings

2018-11-13 08:00:00 | Fibrocell Reports Third Quarter 2018 Financial Results and Recent Highlights

2018-11-09 14:08:07 | Intrexon XON Reports Narrower-Than-Expected Loss in Q3

2018-11-08 08:00:00 | Fibrocell to Host Conference Call and Webcast on Tuesday, November 13, 2018 to Discuss Third Quarter 2018 Financial Results and Recent Highlights

2018-10-25 08:00:00 | Fibrocell Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007

2018-09-26 08:00:00 | Fibrocell to Present at Upcoming Industry and Investor Conferences

2018-09-25 08:00:00 | Fibrocell Awarded $1.4 Million FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa

2018-09-05 08:00:00 | Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma

2018-08-09 08:00:00 | Fibrocell Reports Second Quarter 2018 Financial Results and Recent Highlights

2018-08-09 06:30:00 | Fibrocell Science, Inc. to Host Earnings Call

2018-08-02 08:00:00 | Fibrocell to Host Conference Call and Webcast on Thursday, August 9, 2018 to Discuss Second Quarter 2018 Financial Results and Recent Highlights

2018-07-31 17:09:09 | What's in Store for Intrexon XON This Earnings Season?

2018-07-25 07:35:00 | Free Technical Research on Evolus and Three More Generic Drugs Equities

2018-07-05 16:05:00 | Fibrocell Announces Closing of $4.0 Million Registered Direct Offering

2018-07-02 11:05:35 | Chester County gene therapy company expects $4M direct from direct stock offering

2018-07-02 09:00:00 | Fibrocell Announces $4.0 Million Registered Direct Offering Priced At-the-Market

2018-06-01 08:16:41 | Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO

2018-06-01 07:39:25 | Chester County gene therapy company completes $6M stock sale

2018-06-01 06:57:10 | Fibrocell Science FCSC Sees Hammer Chart Pattern: Time to Buy?

2018-05-31 16:05:00 | Fibrocell Announces Closing of $6.0 Million Registered Direct Offering

2018-05-29 09:20:00 | Fibrocell Announces $6.0 Million Registered Direct Offering Priced At-the-Market

2018-05-24 08:56:09 | Fibrocell Announces One-for-Five Reverse Stock Split

2018-05-23 07:40:00 | Blog Exposure - Fibrocell Presented Update on Interim Results and Progress of its Phase-1/2 Clinical Trial of FCX-007 at International Investigative Dermatology Meeting

2018-05-21 08:59:20 | Benzinga Pro's 5 Stocks To Watch Today

2018-05-21 07:00:00 | Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

2018-05-17 08:27:58 | Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More

2018-05-16 16:05:00 | Fibrocell Announces Oral Presentation at 7th International Investigative Dermatology Meeting

2018-05-10 08:00:00 | Fibrocell Reports First Quarter 2018 Financial Results and Recent Highlights

2018-05-03 08:00:00 | Fibrocell to Host Conference Call and Webcast on Thursday, May 10, 2018 to Discuss First Quarter 2018 Financial Results and Recent Highlights

2018-05-02 10:54:02 | What's in Store for Intrexon XON This Earnings Season?

2018-04-18 08:00:00 | Fibrocell Announces Review of Strategic Alternatives

2018-04-10 08:00:00 | Fibrocell to Present at 6th Annual Cell & Gene Therapy Investor Day and 2018 World Orphan Drug Congress USA

2018-03-19 08:00:00 | Fibrocell Reports 2017 Financial Results and Recent Highlights

2018-03-19 07:42:31 | Does Fibrocell Science Inc’s NASDAQ:FCSC Past Performance Indicate A Stronger Future?

2018-03-19 06:30:00 | Fibrocell Science, Inc. to Host Earnings Call

2018-03-12 08:00:00 | Fibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and Recent Highlights

2018-03-06 08:00:00 | Fibrocell Announces FDA Allowance of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma